{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:08:44Z","timestamp":1793837324067,"version":"4.6.1"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Newborn screening for congenital adrenal hyperplasia using 17-hydroxyprogesterone by immunoassay remains controversial despite screening been available for almost 40 years. Screening is confounded by poor immunoassay specificity, fetal adrenal physiology, stress, and illness which can result in a large number of false positive screening tests. Screening programmes apply higher screening thresholds based on co-variates such as birthweight or gestational age but the false positive rate using immunoassay remains high. Mass spectrometry was first applied to newborn screening for congenital adrenal hyperplasia over 15 years ago. Elevated 17-hydroxprogesterone by immunoassay can be retested with a specific liquid chromatography tandem mass spectrometry assay that may include additional steroid markers. Laboratories register with quality assurance programme providers to ensure accurate steroid measurements. This has led to improvements in screening but there are additional costs and added laboratory workload. The search for novel steroid markers may inform further improvements to screening. Studies have shown that 11-oxygenated androgens are elevated in untreated patients and that the adrenal steroidogenesis backdoor pathway is more active in babies with congenital adrenal hyperplasia. There is continual interest in 21-deoxycortisol, a specific marker of 21-hydroxylase deficiency. The measurement of androgenic steroids and their precursors by liquid chromatography tandem mass spectrometry in bloodspots may inform improvements for screening, diagnosis, and treatment monitoring. In this review, we describe how liquid chromatography tandem mass spectrometry has improved newborn screening for congenital adrenal hyperplasia and explore how future developments may inform further improvements to screening and diagnosis.<\/jats:p>","DOI":"10.3389\/fendo.2023.1226284","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:50:06Z","timestamp":1696308606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives"],"prefix":"10.3389","volume":"14","author":[{"given":"Mark","family":"de Hora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Heather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","article-title":"High frequency of nonclassical steroid 21-hydroxylase deficiency","volume":"37","author":"Speiser","year":"1985","journal-title":"Am J Hum Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/38.9.1830","article-title":"Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays","volume":"38","author":"Wong","year":"1992","journal-title":"Clin Chem"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.04.011","article-title":"Reduced Activity of 11 beta-Hydroxylase Accounts for Elevated 17 alpha-Hydroxyprogesterone in Preterms","volume":"165","author":"Kamrath","year":"2014","journal-title":"J Pediatr-Us."},{"key":"B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/ijns6030067","article-title":"Newborn screening for congenital adrenal hyperplasia: review of factors affecting screening accuracy","volume":"6","author":"Held","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021732","article-title":"Screening for congenital adrenal hyperplasia: Adjustment of 17-hydroxyprogesterone cut-off values to both age and birth weight markedly improves the predictive value","volume":"88","author":"Olgemoller","year":"2003","journal-title":"J Clin Endocr Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2136","article-title":"Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight","volume":"90","author":"van der Kamp","year":"2005","journal-title":"J Clin Endocr Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-02468","article-title":"Combined gestational age- and birth weight-adjusted cutoffs for newborn screening of congenital adrenal hyperplasia","volume":"104","author":"Pode-Shakked","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.08.004","article-title":"Congenital adrenal hyperplasia cases identified by newborn screening in one- and two-screen states","volume":"116","author":"Held","year":"2015","journal-title":"Mol Genet Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3168","article-title":"Newborn screening for congenital adrenal hyperplasia in New Zealand, 1994-2013","volume":"100","author":"Heather","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2011.774","article-title":"Efficiency of neonatal screening for congenital adrenal hyperplasia due to 21-hydroxylase deficiency in children born in mainland France between 1996 and 2003","volume":"166","author":"Coulm","year":"2012","journal-title":"Arch Pediat Adol Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-304473","article-title":"No evidence of an increase in early infant mortality from congenital adrenal hyperplasia in the absence of screening","volume":"99","author":"Hird","year":"2014","journal-title":"Arch Dis Child"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2013.5321","article-title":"Nationwide neonatal screening for congenital adrenal hyperplasia. A 26-year longitudinal prospecttive population-based study","volume":"168","author":"Gidl\u00f6f","year":"2014","journal-title":"JAMA Pediatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.5281","article-title":"Cases of congenital adrenal hyperplasia missed by newborn screening in Minnesota","volume":"307","author":"Sarafoglou","year":"2012","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijns8040056","article-title":"Evaluation of a new laboratory protocol for newborn screening for congenital adrenal hyperplasia in New Zealand","volume":"8","author":"de Hora","year":"2022","journal-title":"Int J Neonatal Screen"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jpeds.2013.01.002","article-title":"Congenital adrenal hyperplasia and the second newborn screen","volume":"163","author":"Chan","year":"2013","journal-title":"J Pediatr-Us"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-1219","article-title":"Comparison of one-tier and two-tier newborn screening metrics for congenital adrenal hyperplasia","volume":"130","author":"Sarafoglou","year":"2012","journal-title":"Pediatrics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032235","article-title":"Steroid profiling by tandem mass spectrometry improves the positive predictive value of newborn screening for congenital adrenal hyperplasia","volume":"89","author":"Minutti","year":"2004","journal-title":"J Clin Endocr Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.027193","article-title":"Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry","volume":"50","author":"Lacey","year":"2004","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2890","article-title":"Newborn screening for congenital adrenal hyperplasia: Additional steroid profile using liquid chromatography-tandem mass spectrometry","volume":"92","author":"Janzen","year":"2007","journal-title":"J Clin Endocr Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.03.048","article-title":"Simultaneous quantification of 17 alpha-OH progesterone, 11-deoxycortisol, Delta 4-androstenedione, cortisol and cortisone in newborn blood spots using liquid chromatography-tandem mass spectrometry","volume":"879","author":"Magnisali","year":"2011","journal-title":"J Chromatogr B"},{"key":"B22","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.33176\/2021Abstracts","article-title":"Congenital adrenal hyperplasia detection and monitoring in dried bloodspots by liquid chromatography tandem mass spectrometry (LC-MS\/MS)","author":"Schick AL","year":"2021","journal-title":"Clin Biochem Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2015.35.6.578","article-title":"Dried blood spot testing for seven steroids using liquid chromatography-tandem mass spectrometry with reference interval determination in the Korean population","volume":"35","author":"Kim","year":"2015","journal-title":"Ann Lab Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4155\/bio.16.6","article-title":"Determination of a steroid profile in heel prick blood using LC-MS\/MS","volume":"8","author":"Boelen","year":"2016","journal-title":"Bioanalysis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2011.07.009","article-title":"An automated method on analysis of blood steroids using liquid chromatography tandem mass spectrometry: Application to population screening for congenital adrenal hyperplasia in newborns","volume":"412","author":"Dhillon","year":"2011","journal-title":"Clin Chim Acta"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.steroids.2011.07.013","article-title":"Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry","volume":"76","author":"Janzen","year":"2011","journal-title":"Steroids"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2011.109","article-title":"Confirmation of congenital adrenal hyperplasia by adrenal steroid profiling of filter paper dried blood samples using ultra-performance liquid chromatography-tandem mass spectrometry","volume":"49","author":"Rossi","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/ijns6030063","article-title":"Evaluation of a two-tier screening pathway for congenital adrenal hyperplasia in the new south wales newborn screening programme","volume":"6","author":"Lai","year":"2020","journal-title":"Int J Neonatal Screen"},{"key":"B29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/ijns5030033","article-title":"Wisconsin's screening algorithm for the identification of newborns with congenital adrenal hyperplasia","volume":"5","author":"Bialk","year":"2019","journal-title":"Int J Neonatal Screen"},{"key":"B30","doi-asserted-by":"publisher","first-page":"109056","DOI":"10.1016\/j.steroids.2022.109056","article-title":"Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China","volume":"185","author":"Zhan","year":"2022","journal-title":"Steroids"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2010.06.029","article-title":"Pilot proficiency testing study for second tier congenital adrenal hyperplasia newborn screening","volume":"411","author":"De Jesus","year":"2010","journal-title":"Clin Chim Acta"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2294","article-title":"Expanded newborn screening for biochemical disorders: The effect of a false-positive result","volume":"117","author":"Gurian","year":"2006","journal-title":"Pediatrics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-007-0691-y","article-title":"Reduction of the false-positive rate in newborn screening by implementation of MS\/MS-based second-tier tests: the Mayo Clinic experience (2004-2007)","volume":"30","author":"Matern","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1203\/PDR.0b013e3181aa3777","article-title":"Use of steroid profiling by UPLC-MS\/MS as a second tier test in newborn screening for congenital adrenal hyperplasia: the utah experience","volume":"66","author":"Schwarz","year":"2009","journal-title":"Pediatr Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233724","article-title":"Storage stability of five steroids and in dried blood spots for newborn screening and retrospective diagnosis of congenital adrenal hyperplasia","volume":"15","author":"Grecso","year":"2020","journal-title":"PloS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1159\/000501396","article-title":"Congenital adrenal hyperplasia: time to replace 17OHP with 21-deoxycortisol","volume":"91","author":"Miller","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jpeds.2021.10.063","article-title":"21-deoxycortisol is a key screening marker for 21-hydroxylase deficiency","volume":"242","author":"Held","year":"2022","journal-title":"J Pediatr"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab464","article-title":"Second-tier testing for 21-hydroxylase deficiency in the Netherlands: A newborn screening pilot study","volume":"106","author":"Stroek","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2013-0154","article-title":"Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital: A retrospective and prospective evaluation","volume":"42","author":"Seo","year":"2014","journal-title":"J Perinat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1159\/000524170","article-title":"Twenty years of neonatal screening for congenital adrenal hyperplasia in north-eastern Italy: role of liquid chromatography-tandem mass spectrometry as a second-tier test","volume":"95","author":"Cavarzere","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000522230","article-title":"Neonatal screening for congenital adrenal hyperplasia in Denmark: 10 years of experience","volume":"95","author":"Lind-Holst","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"B42","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.mce.2017.08.016","article-title":"Intracrine androgen biosynthesis, metabolism and action revisited","volume":"465","author":"Schiffer","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2004.09.004","article-title":"The backdoor pathway to dihydrotestosterone","volume":"15","author":"Auchus","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1997","article-title":"Increased activation of the alternative \"backdoor\" pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis","volume":"97","author":"Kamrath","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jsbmb.2017.07.034","article-title":"Adrenal C11-oxy C21 steroids contribute to the C11-oxy C19 steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone","volume":"174","author":"Barnard","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103217","article-title":"17a-hydroxyprogesterone and 21-desoxyhydrocortisone; their metabolism and possible role in congenital adrenal hyperplasia","volume":"34","author":"Jailer","year":"1955","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-20-0129","article-title":"Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation","volume":"183","author":"Turcu","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsbmb.2015.10.003","article-title":"Chemical derivatization for enhancing sensitivity during LC\/ESI-MS\/MS quantification of steroids in biological samples: a review","volume":"162","author":"Higashi","year":"2016","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4155\/bio.15.176","article-title":"Derivatization of steroids in biological samples for GC-MS and LC-MS analyses","volume":"7","author":"Marcos","year":"2015","journal-title":"Bioanalysis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"462228","DOI":"10.1016\/j.chroma.2021.462228","article-title":"A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry","volume":"1650","author":"Caron","year":"2021","journal-title":"J Chromatogr A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2018.11.035","article-title":"Simultaneous analysis by LC-MS\/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue","volume":"164","author":"Hakkinen","year":"2019","journal-title":"J Pharm BioMed Anal"},{"key":"B54","doi-asserted-by":"publisher","first-page":"16993","DOI":"10.1038\/s41598-018-35007-0","article-title":"A novel targeted analysis of peripheral steroids by ultra-performance supercritical fluid chromatography hyphenated to tandem mass spectrometry","volume":"8","author":"de Kock","year":"2018","journal-title":"Sci Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s13659-019-0204-3","article-title":"Quantitative-profiling method of serum steroid hormones by hydroxylamine-derivatization HPLC-MS","volume":"9","author":"Liu","year":"2019","journal-title":"Nat Prod Bioprospect"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1226284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T04:50:10Z","timestamp":1696308610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1226284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":55,"alternative-id":["10.3389\/fendo.2023.1226284"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1226284","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"article-number":"1226284"}}